tbuckley/cabot-search huggingface dataset:
Abstract P4-13-20: Activity of HP-based therapies as third and later lines for the treatment of HER2-positive metastatic breast cancer: A retrospective study from a single institution
Authors: D Argolo, M Friedman, L Smyth, N Iyengar, J Singh, S Patil, L Norton, J Baselga, C Hudis, C Dang
Journal: Cancer Research (2016)

Abstract Background: Dual anti-HER2 blockade with trastuzumab and pertuzumab (HP) plus chemotherapy is an effective therapy (Rx) in the 1st-line setting for HER2-positive metastatic breast cancer (MBC). Our single arm phase II study included patients (pts) treated with HP plus paclitaxel in the 2nd-line setting with progression-free survival (PFS) benefit. Recently, we reported results from a retrospective study of pts treated at our institution, suggesting a longer PFS for those who received HP-based Rxs when compared to any other anti-HER2 based Rxs in the 2nd-line setting. To further assess the activity of this combination in later Rx lines, we conducted a retrospective analysis of pts with HER2-positive MBC who had progressive disease after 2nd-line and were treated with HP-based Rxs in the 3rd and later lines at MSKCC. Historically, the median (med) PFS in this setting with trastuzumab-based Rx is about 3-4 months. Methods: Pts diagnosed with HER2-positive MBC and treated with HP-based Rxs at MSKCC between 1-1-2011 and 03-30-2015 and who progressed on 2nd-line Rx were identified through an institutional database. Primary endpoint was PFS in 3rd and later treatment lines. Results: 70 pts who received any HP-based Rx in the 3rd or later lines of treatment were eligible. The med number of prior anti-HER2 Rx was 3. The baseline characteristics and Rxs are summarized in Table 1. The med PFS for the entire cohort was 5.7 months (95% CI, 4.8-6.5). Conclusions: In this retrospective analysis involving heavly pretreated patients, HP-based Rx appears to be an active regimen and compares favorably to historical data. This supports the NCCN endorsement of HP-based Rx in later lines if HP has not been delivered previously. Baseline Characteristics and treatments (n=70)Characteristic(n)(%)Age Median56 Range27-83 Gender Female70100.0Male00.0Race Black1014.3White5477.1Other68.6Ethnicity Non Hispanic6694.3Hispanic45.7ER/PR status ER and PR negative2738.6ER and/or PR positive4361.4Type of disease Non visceral1622.9Visceral5477.1Visceral CNS2130.0Anti-HER2 in early stage Yes2941.4No4158.6Line of therapy 3rd line1927.14th line1521.45th line912.96th line912.97th line811.48th line and beyond1014.3HP-based regimens Chemotherapy + HP5477.1Endocrine therapy + HP57.1HP alone912.9Other22.9 Citation Format: Argolo D, Friedman M, Smyth L, Iyengar N, Singh J, Patil S, Norton L, Baselga J, Hudis C, Dang C. Activity of HP-based therapies as third and later lines for the treatment of HER2-positive metastatic breast cancer: A retrospective study from a single institution. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-13-20.
CASE REPORTS
Authors: J. WEATHERLY, L. M. VILLIEN
Journal: American Journal of Psychiatry (1958)

1. A 53-year-old man with an acute psychotic depression received electric shock treatment a year after an aneurysm of his descending thoracic aorta was replaced by a homograph. 2. Although the patient also had hypertension, good clinical results were obtained without the development of untoward cardiovascular effects. 3. It is not considered that an aortic homograph is a contraindication to electric shock treatment.
Outdoor second-hand cigarette smoke significantly affects air quality
Authors: Ario Alberto Ruprecht, Cinzia De Marco, Paolo Pozzi, Roberto Mazza, Elena Munarini, Adriano Di Paco, Paolo Paredi, Giovanni Invernizzi, Roberto Boffi
Journal: European Respiratory Journal (2016)

Second-hand smoke (SHS) may be significantly elevated outdoors and when adjacent to smoking areas [1, 2]. This is of concern as SHS exposure is linked to adverse health outcomes, including respiratory disorders, cardiovascular diseases, and lung cancer [3–5]. Exposure to cancer-causing chemicals in outdoor areas is likely to occur in the presence of cigarette smoke [6], and worryingly, short periods of exposure to SHS are related to detectable levels of carcinogenic tobacco-specific nitrosamines in nonsmoking subjects [7]. Air quality is worse in a pedestrian area frequented by smokers compared with a high-traffic zone <http://ow.ly/DMW83007Xmo> We wish to dedicate this work to Giovanni Invernizzi who strongly contributed to this study before he passed away.
Pathophysiology of Raynaud's phenomenon.
Authors: Y Mishima
Journal: BMJ (1980)

tachycardia were more likely to die suddenly during the followup period of one to four years.10At the very least, the evidence suggests that control of ventricular arrhythmias may help prevent sudden death.As more experience is gained the prospects seem better for the control of these arrhythmias with drugs.8 11Long-term, ambulatory electrocardiographic monitoring will be required in all patients with hypertrophic cardiomyopathy so that serious ventricular arrhythmias may be detected and treated early on.
The Radical Surgical Treatment of Gastric Cancer&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/xref&gt;
Authors: George T. Pack, M. D.
Journal: JNCI Journal of the National Cancer Institute (1947)

The Radical Surgical Treatment of Gastric Cancer Get access George T. Pack, M. D. George T. Pack, M. D. Gastric Service of the Memorial Hospital for the Treatment of Cancer and Allied Diseases, New York City Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 7, Issue 5, April 1947, Pages 337–344, https://doi.org/10.1093/jnci/7.5.337 Published: 01 April 1947
Prevalence of Excess Sodium Intake in the United States — NHANES, 2009–2012
Authors: Sandra L. Jackson, Sallyann M. Coleman King, Lixia Zhao, Mary E. Cogswell
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

Hypertension, a major risk factor for cardiovascular diseases, occurs among 29% of U.S. adults, and lowering excess sodium intake can reduce blood pressure (1-3). The 2015-2020 Dietary Guidelines for Americans recommend consuming less than 2,300 mg dietary sodium per day for persons aged ≥14 years and less for persons aged 2-13 years.* To examine the current prevalence of excess sodium intake among Americans overall, and among hypertensive adults, CDC analyzed data from 14,728 participants aged ≥2 years in the 2009-2012 National Health and Nutrition Examination Survey (NHANES). Eighty-nine percent of adults and over 90% of children exceeded recommendations for sodium intake. Among hypertensive adults, 86% exceeded 2,300 mg dietary sodium per day. To address the high prevalence of excess sodium consumption in the U.S. population, the Institute of Medicine (IOM) recommended reducing sodium in the food supply, as excess sodium added to foods during commercial processing and preparation represents the main source of sodium intake in U.S. diets (4).
Abstract P3-01-13: Risk factors of non-sentinel lymph node metastasis in breast cancer patients with metastatic sentinel lymph node
Authors: J Huang, X Chen, K Shen, Y Li, W Chen, J He, L Zhu, O Huang, Y Zong, X Fei, X Jin
Journal: Cancer Research (2016)

Abstract Objective To study the factors influencing the non-sentinel lymph node(NSLN) status and to assess Memorial Sloan-Kettering Cancer Center (MSKCC) nomogram performance in predicting SLN metastases in a sentinel lymph node(SLN) positive Chinese breast cancer population. Methods Data were collected from breast cancer patients who were diagnosed with pathological positive sentinel lymph node and received further axillary lymph node dissection(ALND) in Shanghai Ruijin Hospital from January 2011 to August 2014. Use MSKCC nomogram to calculate each patient's NSLN metastasis risk score. The receiver operator characteristic curve(ROC curve)and the area under the ROC curve(AUC)was used to assess the predictive accuracy of the model. Results Among the 1147 patients who received sentinel biopsy in our center, 150 SLN positive patients who received ALND were enrolled in this study. By univariate analysis, multifocal breast cancer (P = 0.017), SLN+/SLN ratio (P = 0.010) and axillary lymphadenopathy displayed by ultrasound(P = 0.005) are the influencing factors of NSLN metastases. By multivariate analysis, multifocal breast cancer (OR 7.25, 95% CI 1.73∼30.43, P = 0.007), SLN+/SLN ratio≥0.5 (OR 2.564, 95% CI 1.22∼5.39, P = 0.013) and axillary lymphadenopathy displayed by ultrasound (OR 2.471, 95% CI 1.18∼5.19, P = 0.017) are the independent influencing factors of NSLN metastases. The AUC of MSKCC nomogram in this population is 0.677. Conclusion For breast cancer patients with positive sentinel lymph node, multifocality, SLN+/SLN ratio and axillary lymphadenopathy displayed by ultrasound is related to NSLN metastasis. MSKCC has low accuracy in predicting NSLN status of this population. Citation Format: Huang J, Chen X, Shen K, Li Y, Chen W, He J, Zhu L, Huang O, Zong Y, Fei X, Jin X. Risk factors of non-sentinel lymph node metastasis in breast cancer patients with metastatic sentinel lymph node. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-01-13.
Urinary content of aquaporin 1 and 2 in nephrogenic diabetes insipidus.
Authors: P M Deen, R A van Aubel, A F van Lieburg, C H van Os
Journal: Journal of the American Society of Nephrology (1996)

Hereditary nephrogenic diabetes insipidus (NDI) is caused by mutations in either the X-chromosomal gene encoding the vasopressin V2-receptor or in the autosomal gene encoding aquaporin-2. Expressed in Xenopus oocytes, the AQP2 gene mutations found in NDl have been shown to reduce the stability of the encoded protein. This study investigated the in vivo stability of mutant and wild-type aquaporin-2 proteins by measuring their excretion in urine of NDl patients and healthy individuals. On immunoblots, the urine samples from healthy volunteers revealed clear aquaporin-1 and aquaporin-2 signals in antidiuretic but not diuretic states. In the urine of a female patient, whose NDl is explained by low expression of the wild-type V2-receptor gene, aquaporin-2 excretion was high and comparable with that in a healthy individual during antidiuresis. In the urine of a male patient with a non-sense mutation in the V2-receptor gene, a weak aquaporin-2 signal was detected. In NDl patients with mutations in the aquaporin-2 gene, aquaporin-2 could not be detected in urine, suggesting a low stability of mutant aquaporin-2 proteins. In four out of seven NDl patients, aquaporin-1 excretion was relatively high, which suggests a compensatory increase in proximal reabsorption in NDl.
Biomarkers for Prediction of Cardiovascular Events
Authors: Paul M Ridker, Nancy R Cook
Journal: New England Journal of Medicine (2007)

sug-gest that novel biomarkers in aggregate have lit-tle influence on the prediction of first cardiovas-cular events or death. We wonder whether there were sufficient analyses to warrant this conclusion. As described, there were only 68 “major” cardio-vascular events in women and 101 in men. In the crucial multimarker analyses, a quarter of these events were eliminated owing to the obligatory in-clusion of the urinary albumin-to-creatinine ratio in all the multimarker scores. Would these scores have been more useful if urine biomarkers had been excluded and 100% of the events included?Second, it is surprising that a study of risk prediction would include prevalent cardiovascular disease, yet analyses that include stroke would not consider atrial fibrillation. Finally, the inclu-sion of heart failure and coronary insufficiency as “major” cardiovascular events is problematic, since they are not included in the more restrictive defi-nition of “hard” events (myocardial infarction and death from coronary causes) outlined by the third report of the Adult Treatment Panel (ATP III) of the National Cholesterol Education Program. The ATP III definition is currently recommended to determine lipid treatment goals and aspirin use.
FDG PET/CT Findings of the Recurrent Posttransplantation Lymphoproliferative Disorder in a Pediatric Liver Transplant Recipient With Right Leg Pain as the Only Complaint
Authors: Xia Bai, Hua Yang, Hongming Zhuang
Journal: Clinical Nuclear Medicine (2015)

The most commonly observed symptoms of posttransplantation lymphoproliferative disorder (PTLD) after a liver transplantation were diarrhea and fever. Although PTLD can involve bones, bone pain is a rare manifestation of PTLD, much less to say a sole presentation. We report a case of a pediatric patient with recurrent PTLD after liver transplantation, whose only complaint was right tibial pain. FDG PET/CT revealed not only hypermetabolic activity in the right proximal tibia but also in many other parts of the body. Recurrent PTLD was confirmed after bone biopsy.
Limitations of Brief Hospital Treatment
Authors: S Reibel, M I Herz
Journal: American Journal of Psychiatry (1976)

A total of 175 newly admitted inpatients who lived with their families were randomly assigned to three treatment groups: standard inpatient care and brief hospitalization with and without transitional day care. Case reports of 6 of the 9 patients considered "study failures" illustrate that effective postdischarge adaptation is limited by the patients' degree of impairment as well as the family and community capacity to accept them. Although rapid return to the community is beneficial to many patients, rigid adherence to this policy is neither wise nor clinically effective.
Age- and Tumor Subtype–Specific Breast Cancer Risk Estimates for <i>CH</i><i>EK</i><i>2</i>*1100delC Carriers
Authors: Marjanka K. Schmidt, Frans Hogervorst, Richard van Hien, Sten Cornelissen, Annegien Broeks, Muriel A. Adank, Hanne Meijers, Quinten Waisfisz, Antoinette Hollestelle, Mieke Schutte, Ans van den Ouweland, Maartje Hooning, Irene L. Andrulis, Hoda Anton-Culver, Natalia N. Antonenkova, Antonis C. Antoniou, Volker Arndt, Marina Bermisheva, Natalia V. Bogdanova, Manjeet K. Bolla, Hiltrud Brauch, Hermann Brenner, Thomas Brüning, Barbara Burwinkel, Jenny Chang-Claude, Georgia Chenevix-Trench, Fergus J. Couch, Angela Cox, Simon S. Cross, Kamila Czene, Alison M. Dunning, Peter A. Fasching, Jonine Figueroa, Olivia Fletcher, Henrik Flyger, Eva Galle, Montserrat García-Closas, Graham G. Giles, Lothar Haeberle, Per Hall, Peter Hillemanns, John L. Hopper, Anna Jakubowska, Esther M. John, Michael Jones, Elza Khusnutdinova, Julia A. Knight, Veli-Matti Kosma, Vessela Kristensen, Andrew Lee, Annika Lindblom, Jan Lubinski, Arto Mannermaa, Sara Margolin, Alfons Meindl, Roger L. Milne, Taru A. Muranen, Polly A. Newcomb, Kenneth Offit, Tjoung-Won Park-Simon, Julian Peto, Paul D.P. Pharoah, Mark Robson, Anja Rudolph, Elinor J. Sawyer, Rita K. Schmutzler, Caroline Seynaeve, Julie Soens, Melissa C. Southey, Amanda B. Spurdle, Harald Surowy, Anthony Swerdlow, Rob A.E.M. Tollenaar, Ian Tomlinson, Amy Trentham-Dietz, Celine Vachon, Qin Wang, Alice S. Whittemore, Argyrios Ziogas, Lizet van der Kolk, Heli Nevanlinna, Thilo Dörk, Stig Bojesen, Douglas F. Easton
Journal: Journal of Clinical Oncology (2016)

CHEK2*1100delC is a well-established breast cancer risk variant that is most prevalent in European populations; however, there are limited data on risk of breast cancer by age and tumor subtype, which limits its usefulness in breast cancer risk prediction. We aimed to generate tumor subtype- and age-specific risk estimates by using data from the Breast Cancer Association Consortium, including 44,777 patients with breast cancer and 42,997 controls from 33 studies genotyped for CHEK2*1100delC.
Premenstrual symptoms in black and white community samples
Authors: A L Stout, T A Grady, J F Steege, D G Blazer, L K George, M L Melville
Journal: American Journal of Psychiatry (1986)

Premenstrual syndrome specialty clinics are reported to be almost exclusively attended by white women. This racial discrepancy has raised the question of whether there is a lower prevalence or severity of symptoms during the premenstruum among black women. The authors evaluated selected premenstrual symptoms in a representative community-based sample and found no difference in the prevalence or severity of premenstrual symptoms reported by black and white women, except for a higher prevalence of food cravings among blacks. Exploration of broader sociocultural factors may explain the observed racial difference in seeking help for premenstrual complaints.
Hospice Use Following Implantable Cardioverter-Defibrillator Implantation in Older Patients
Authors: Daniel B. Kramer, Matthew R. Reynolds, Sharon-Lise Normand, Craig S. Parzynski, John A. Spertus, Vincent Mor, Susan L. Mitchell
Journal: Circulation (2016)

Background— Older recipients of implantable cardioverter-defibrillators (ICDs) are at increased risk for short-term mortality in comparison with younger patients. Although hospice use is common among decedents aged &gt;65, its use among older ICD recipients is unknown. Methods and Results— Medicare patients aged &gt;65 matched to data in the National Cardiovascular Data Registry – ICD Registry from January 1, 2006 to March 31, 2010 were eligible for analysis (N=194 969). The proportion of ICD recipients enrolled in hospice, cumulative incidence of hospice admission, and factors associated with time to hospice enrollment were evaluated. Five years after device implantation, 50.9% of patients were either deceased or in hospice. Among decedents, 36.8% received hospice services. The cumulative incidence of hospice enrollment, accounting for the competing risk of death, was 4.7% (95% confidence interval [CI], 4.6%–4.8%) within 1 year and 21.3% (95% CI, 20.7%–21.8%) at 5 years. Factors most strongly associated with shorter time to hospice enrollment were older age (adjusted hazard ratio, 1.77; 95% CI, 1.73–1.81), class IV heart failure (versus class I; adjusted hazard ratio, 1.79; 95% CI, 1.66–1.94); ejection fraction &lt;20 (adjusted hazard ratio, 1.57; 95% CI, 1.48–1.67), and greater hospice use among decedents in the patients’ health referral region. Conclusions— More than one-third of older patients dying with ICDs receive hospice care. Five years after implantation, half of older ICD recipients are either dead or in hospice. Hospice providers should be prepared for ICD patients, whose clinical trajectories and broader palliative care needs require greater focus.
The role of ALDH1 and CD133 expression as stem cell tumor marker in early-stage NSCLC.
Authors: Ana Lopez-Gonzalez, Clara Salas, Mariano Provencio, Nieves Alonso Orcajo, Cristina Diez-Tascon, Engracia Santin, M.Eva Vallejo-Pascual, Carlos Gamallo
Journal: Journal of Clinical Oncology (2015)

e13508 Background: A 70% of patients with non-small cell lung cancer (NSCLC) stage I die of their disease within five years of diagnosis. Cancer stem cells (CSC) have been described as poor prognostic factors. This is a group of tumorigenic cells with capacity for self-renewal and differentiation, and also for migration and recurrence. Two of the markers used to identify these CSC are Aldehyde dehydrogenase 1 (ALDH1) and CD133. Methods: We conducted a retrospective study of 78 patients diagnosed with stage I NSCLC in the Hospital Universitario Puerta de Hierro between 2004 and 2009 who had not received adjuvant chemotherapy, and with a minimum follow-up time of 24 months. The expression of CD133 and ALDH1 was determined by immunohistochemistry and also EGFR mutations in adenocarcinomas. We analyzed the relationship between ALDH1 and CD133 with various clinicopathological variables, as well as the survival of these patients. Results: We found differences between the two markers with different histological subtypes. ALDH1 expression was most frequent in squamous cell carcinomas and CD133 expression was exclusive between adenocarcinomas. We found no co-expression of the two markers of CSC in any of the cases reviewed. We also found no association between ALDH1 and CD133 expression and other poor prognostic factors (high degree of differentiation, tumor size or invasion of visceral pleura). Furthermore, there were no differences in survival based on the expression of ALDH1 and CD133. We describe for the first time the nuclear expression of ALDH1, probably related to a better prognosis in these patients. No relation was found between EGFR mutations and ALDH1 and CD133 expression. Conclusions: We found no co-expression of ALDH1 and CD133 in any of our patients. Therefore, we have not managed to identify CSC in stage I NSCLC using as markers ALDH1 and CD133. ALDH1 is expressed in both the nucleus and cytoplasm. ALDH1 cytoplasmic expression has no influence on the survival of patients. The nuclear expression of ALDH1 can be associated with a better prognosis. The expression of CD133 is associated with a lower relapse rate. CD133 and ALDH1 are not associated with the presence of EGFR mutations in adenocarcinomas.
Factor VIII–Mimetic Function of Humanized Bispecific Antibody in Hemophilia A
Authors: Midori Shima, Hideji Hanabusa, Masashi Taki, Tadashi Matsushita, Tetsuji Sato, Katsuyuki Fukutake, Naoki Fukazawa, Koichiro Yoneyama, Hiroki Yoshida, Keiji Nogami
Journal: New England Journal of Medicine (2016)

In patients with severe hemophilia A, standard treatment is regular prophylactic and episodic intravenous infusions of factor VIII. However, these treatments are burdensome, especially for children, and may lead to the formation of anti–factor VIII alloantibodies (factor VIII inhibitors). Emicizumab (ACE910), a humanized bispecific antibody mimicking the cofactor function of factor VIII, was developed to abate these problems.
Recanalization of Organized Thrombi Demonstrated by Coronary CT Angiography Compared With OCT
Authors: Dong Hyun Yang, Soo-Jin Kang, Young-Hak Kim, Joon-Won Kang, Jung-Min Ahn, Duk-Woo Park, Seung-Whan Lee, Cheol Whan Lee, Seong-Wook Park, Seung-Jung Park, Tae-Hwan Lim
Journal: JACC. Cardiovascular imaging (2016)
Use of ErbB-1 and ErbB-2 to Select Endocrine Therapy for Breast Cancer: Will It Play in Peoria?
Authors: Kathleen I. Pritchard
Journal: Journal of Clinical Oncology (2001)

Article Tools EDITORIALS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2001.19.18.3795 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11559715 Use of ErbB-1 and ErbB-2 to Select Endocrine Therapy for Breast Cancer: Will It Play in Peoria? Kathleen I. PritchardxKathleen I. PritchardSearch for articles by this author Show More Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada https://doi.org/10.1200/JCO.2001.19.18.3795 First Page Full Text PDF Figures and Tables © 2001 by American Society of Clinical Oncology